Table 2.
MoS2-based nanocomposites for cancer imaging and therapy.
| Materials | Physically trigger | Therapy | Imaging modes | In vivo models | Therapeutic effect | Refs |
|---|---|---|---|---|---|---|
| DOX-MoS2/Pt | / | drug delivery | / | / | / | [378] |
| DOX-PSMS-PEG | NIR laser(808 nm) | drug delivery | / | / | / | [206] |
| DOX/DNA/MoS2-NS | ATP | drug delivery | / | / | / | [379] |
| MoS2/GO@DOX | GO-targeting | drug delivery | / | Mice bearing B16 tumor | Completely eradicate tumor | [213] |
| DOX@MoS2-PEI-HA | NIR laser(808 nm)/pH/HAase | drug delivery | PET | Mice bearing MCF-7-ADR tumor | Completely eradicate tumor | [181] |
| F–MoS2 NSs. | NIR laser(808 nm) | PTT | / | / | / | [63] |
| MoS2-CS-Cype | NIR laser(808 nm) | PTT | / | / | / | [380] |
| MoS2-PEG nanoflakes | NIR laser(808 nm) | PTT | / | Mice bearing 4T1 tumor | / | [244] |
| MoS2-PEG | NIR laser(808 nm) | PTT | / | Mice bearing 4T1 tumor | Delay tumor growth | [240] |
| MoS2-PPEG | NIR laser(808 nm) | PTT | / | Mice bearing 4T1 tumor | Reduce tumor volume | [258] |
| MoS2-GSH nanodots | NIR laser(808 nm) | PTT | PA | Mice bearing 4T1 tumor | Completely eradicate tumor | [252] |
| RGD-QD-MoS2 NSs | NIR laser(785 nm) | PTT | NIRF | Mice bearing HeLa tumor | Reduce tumor volume | [][][]139] |
| MoS2@PZAC | NIR laser(808 nm) | PTT | MRI | Mice bearing 4T1 tumor | Reduce tumor volume | [178] |
| MoS2-Gd-BSA | NIR laser(808 nm) | PTT | MR/PA | Mice bearing 4T1 tumor | Completely eradicate tumor | [305] |
| Layered MoS2 hollow spheres | NIR laser(808 nm) | PTT | CT/IR | Rabbit bearing VX2 tumor | Completely eradicate tumor | [242] |
| HA-MoS2 | NIR laser(808 nm) | PTT | FL/PA | Mice bearing HCT116 tumor | Reduce tumor volume | [293] |
| 64Cu-MoS2-IO-(d)PEG | NIR laser(808 nm) | PTT | MRI/PA/PET | Mice bearing 4T1 tumor | Reduce tumor volume | [177] |
| p-MoS2/n-rGO-MnO2-PEG | NIR laser(980 nm) | PDT | / | / | / | [262] |
| MoS2-PEG/Ce6 | NIR laser(808 nm)/660 nm | PTT/PDT | / | Mice bearing 4T1 tumor | Delay tumor growth | [269] |
| MoS2-LA-K11(DMA)-TBO (MKT) | NIR laser(808 nm)/630 nm | PTT/PDT | / | Mice bearing SCC-7 tumor | Reduce tumor volume | [270] |
| MoS2-UCNPs-FA/ZnPc | NIR laser(808 nm)/980 nm | PTT/PDT | NIRF | Mice bearing HCC38 tumor | Delay tumor growth | [289] |
| PEG-MoS2-Au-Ce6 | NIR laser(808 nm)/660 nm | PTT/PDT | CT/NIRF | Mice bearing 4T1 tumor | Reduce tumor volume | [381] |
| Cy5.5-BSA-MoS2 | NIR laser(808 nm) | PTT/PDT | FL/PAT | Mice bearing HepG2 tumor | Completely eradicate tumor | [292] |
| MoS2-UCNPs@Ce6@SiO2 | NIR laser(808 nm) | PTT/PDT | CT/MRI/UCL | Mice bearing U14 tumor | Reduce tumor volume | [382] |
| BSA-MoS2 | MW irradiation | MW thermal therapy | / | Mice bearing H22 tumor models | Completely eradicate tumor | [279] |
| MoS2 encapsulated in microcapsules | MW irradiation | MW thermal therapy | CT | Rabbit bearing VX2 tumor | Completely eradicate tumor | [280] |
| sandwich-like MoS2@MOS | NIR laser(808 nm) | PTT/drug delivery | / | / | / | [334] |
| Fe3O4@MoS2@ZnO-DOX | NIR laser(808 nm) | PTT/drug delivery | / | / | / | [320] |
| HMSNs/DOX@MoS2/Tf | NIR laser(808 nm) | PTT/drug delivery | / | / | / | [207] |
| Mn-doped Fe3O4@MoS2 | NIR laser(808 nm) | PTT/drug delivery | MRI | / | / | [307] |
| PMO-DOX@MoS2-PEG | NIR laser(808 nm) | PTT/drug delivery | / | Mice bearing MCF-7 tumor | Delay tumor growth | [322] |
| MoS2-HPG-DOX | NIR laser(808 nm) | PTT/drug delivery | / | Mice bearing B16 tumor | Delay tumor growth | [325] |
| MoS2-PEG-FA/DOX | NIR laser(808 nm) | PTT/drug delivery | / | Mice bearing 4T1 tumor | Delay tumor growth | [68] |
| MoS2/HSA-DOX | NIR laser(808 nm) | PTT/drug delivery | / | Mice bearing MCF-7 tumor | Completely eradicate tumor | [328] |
| HA-PEI-LA-MoS2-PEG@(DOX/Mel) | NIR laser(808 nm)/pH | PTT/drug delivery | / | Mice bearing MCF-7 tumor | Reduce tumor volume | [314] |
| MoS2-Lipid-DOX | NIR laser(808 nm)/pH | PTT/drug delivery | / | Mice bearing 4T1tumor | Reduce tumor volume | [326] |
| NIR-CD/DOX/MoS2 | NIR laser(808 nm) | PTT/drug delivery | CT | Mice bearing 4T1tumor | Completely eradicate tumor | [383] |
| MoS2-HA-DTPA-Gd/Gef | NIR laser(808 nm) | PTT/drug delivery | MRI | Mice bearing A549 tumor | Reduce tumor volume | [384] |
| Fe3O4@MoS2-PEG(DOX)-2DG | NIR laser(808 nm) | PTT/drug delivery | MRI | Mice bearing MDA-MB-23 tumor | Reduce tumor volume | [303] |
| MoS2-CS-DOX | NIR laser(808 nm) | PTT/drug delivery | CT | Mice bearing Panc-1 tumor | Reduce tumor volume | [237] |
| PLGA/MoS2/DOX (PMD) | NIR laser(808 nm) | PTT/drug delivery | PA | Mice bearing 4T1 tumor | Completely eradicate tumor | [290] |
| MoS2/Cu1.8S/DOX | NIR laser(980 nm) | PTT/drug delivery | PLI/PAT/PTI | Mice bearing A549 tumor | Completely eradicate tumor | [295] |
| MoS2@Fe3O4-ICG/Pt(IV) | NIR laser(808 nm) | PTT/PDT/drug delivery | MR/IR/PA | Mice bearing H22 tumor | Completely eradicate tumor | [301] |
| MoS2-PEG-PEI/siPLK1 | / | gene delivery | / | / | / | [352] |
| G5-MoS2/Bcl-2 siRNA | NIR laser(808 nm) | PTT/gene delivery | / | Mice bearing 4T1 tumor | Delay tumor growth | [363] |
| FA/MoS2/siRNA (HDAC1+KRAS) | NIR laser(808 nm) | PTT/gene delivery | / | Mice bearing Panc-1 tumor | Delay tumor growth | [361] |
| MoS2-AKT scaffolds | NIR laser(808 nm) | PTT/tissue regeneration | / | Mice bearing Saos-2 tumor | Reduce tumor volume | [346] |
| AuNBPs@MoS2 | NIR laser(808 nm) | PTT/CDT | TPF | / | / | [369] |
| MoS2@PANI | NIR laser(808 nm) | PTT/RT | CT/PA | Mice bearing 4T1 tumor | Delay tumor growth | [189] |
| MoS2-PEG-CpG | NIR laser(808 nm) | PTT/immunotherapy | / | / | / | [366] |
| FePt/MoS2-FA | NIR laser(808 nm) | PTT/drug delivery/immunotherapy | CT/MRI | Mice bearing 4T1 tumor | Completely eradicate tumor | [374] |
| PC10A/DOX/MoS2 | NIR laser(808 nm) | PTT/PDT/drug delivery/immunotherapy | / | Mice bearing 4T1 tumor | Completely eradicate tumor | [377] |